ARAV / Is Aravive (ARAV) Outperforming Other Medical Stocks This Year?

Aravive (ARAV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy). more_horizontal

Aravive (ARAV) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.30. This compares to loss of $0.6 more_horizontal

Aravive (NASDAQ: ARAV ) stock is plummeting on Thursday following the release of results from a Phase 3 clinical trial. The bad news hitting ARAV sto more_horizontal

Aravive (ARAV) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the st more_horizontal

Aravive (ARAV) delivered earnings and revenue surprises of -39.39% and 298.38%, respectively, for the quarter ended December 2022. Do the numbers hold more_horizontal

Analysts like these penny stocks but is it time to buy or not? The post Best Penny Stocks To Buy? more_horizontal

HOUSTON, Feb. 13, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted more_horizontal

HOUSTON, Feb. 13, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted more_horizontal